Biocon, Ltd. has announced a partnership with digital therapeutics specialist Voluntis to develop and distribute Insulia, a digital therapeutic product to support people with type 2 diabetes on insulin therapy. Insulia provides automated insulin dose recommendations enabling people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress.
The global collaboration agreement between Biocon and Voluntis will target
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?